Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma

被引：0
|
作者：
Ryusei Matsuyama
Ryutaro Mori
Yohei Ota
Yuki Homma
Yasuhiro Yabusita
Seigo Hiratani
Takashi Murakami
Yu Sawada
Kentaro Miyake
Yasuhiro Shimizu
Takafumi Kumamoto
Itaru Endo
机构：
[1] Yokohama City University Graduate School of Medicine,Department of Gastroenterological Surgery
来源：
Annals of Surgical Oncology | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2393 / 2405
页数：12
相关论文
共 50 条
  • [1] ASO Visual Abstract: Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma
    Matsuyama, Ryusei
    Mori, Ryutaro
    Ota, Yohei
    Homma, Yuki
    Yabusita, Yasuhiro
    Hiratani, Seigo
    Murakami, Takashi
    Sawada, Yu
    Miyake, Kentaro
    Shimizu, Yasuhiro
    Kumamoto, Takafumi
    Endo, Itaru
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (04) : 2406 - 2406
  • [2] Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact
    Murakami, Yoshiaki
    Uemura, Kenichiro
    Sudo, Takeshi
    Hashimoto, Yasushi
    Kondo, Naru
    Nakagawa, Naoya
    Takahashi, Shinya
    Sueda, Taijiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 37 - 47
  • [3] Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact
    Yoshiaki Murakami
    Kenichiro Uemura
    Takeshi Sudo
    Yasushi Hashimoto
    Naru Kondo
    Naoya Nakagawa
    Shinya Takahashi
    Taijiro Sueda
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 37 - 47
  • [4] Impact of Neoadjuvant Chemotherapy With Gemcitabine Plus Nab-paclitaxel on the Treatment for Borderline Resectable Pancreatic Cancer
    Miyasaka, Y.
    Ohtsuka, T.
    Kimura, R.
    Mori, Y.
    Nakata, K.
    Nakamura, M.
    PANCREAS, 2019, 48 (10) : 1492 - 1492
  • [5] Efficacy of Neoadjuvant Chemotherapy Using Gemcitabine and S-1 for Resectable and Borderline Resectable Pancreatic Cancer
    Aoki, T.
    Mori, S.
    Sakuraoka, Y.
    Suzuki, T.
    Nishi, Y.
    Arakawa, T.
    Shimizu, T.
    Tago, K.
    Park, K. H.
    Harada, N.
    Shiraki, T.
    Iso, Y.
    Kubota, K.
    PANCREAS, 2019, 48 (10) : 1404 - 1404
  • [6] The clinical impact and analysis for neoadjuvant chemotherapy against borderline resectable pancreatic cancer: Gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel
    Takano, Shigetsugu
    Yoshitomi, Hideyuki
    Kagawa, Shingo
    Furukawa, Katsunori
    Takayashiki, Tsukasa
    Kuboki, Satoshi
    Suzuki, Daisuke
    Sakai, Nozomu
    Mishima, Takashi
    Nakadai, Eri
    Ohtsuka, Masayuki
    CANCER RESEARCH, 2019, 79 (24)
  • [7] Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer
    Yabushita, Yasuhiro
    Matsuyama, Ryusei
    Miyake, Kentaro
    Homma, Yuki
    Kumamoto, Takafumi
    Misumi, Toshihiro
    Hata, Masaharu
    Yamanaka, Shoji
    Fujii, Satoshi
    Endo, Itaru
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2023, 30 (04) : 493 - 502
  • [8] Benefits of neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma
    Hirashita, Teijiro
    Tada, Kazuhiro
    Nagasawa, Yuiko
    Orimoto, Hiroki
    Kawamura, Masahiro
    Fujinaga, Atsuro
    Takayama, Hiroomi
    Kawano, Yoko
    Masuda, Takashi
    Endo, Yuichi
    Inomata, Masafumi
    MOLECULAR AND CLINICAL ONCOLOGY, 2025, 22 (02)
  • [9] Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma
    Suzuki, Takashi
    Mori, Shozo
    Shimizu, Takayuki
    Tago, Kazuma
    Harada, Nobuhiro
    Park, Kyung-Hwa
    Sakuraoka, Yuhki
    Shiraki, Takayuki
    Iso, Yukihiro
    Aoki, Taku
    Kubota, Keiichi
    IN VIVO, 2019, 33 (06): : 2027 - 2035
  • [10] ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes
    Miyasaka, Yoshihiro
    Nakamura, Masafumi
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (Suppl 3) : S739 - S740
12345